This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignees: Eisai R&d Management Co., Ltd., Merck Sharp + Dohme Corp.. Active years: 2021.
Company Filing History:
1 out of 530 
1 out of 2,405 
Years Active: 2021
Title: Gursel Aktan: Innovator in Cancer Treatment
Introduction
Gursel Aktan is a notable inventor based in North Wales, PA (US). He has made significant contributions to the field of cancer treatment through his innovative research and development efforts. His work focuses on combination therapies that enhance the effectiveness of existing cancer treatments.
Latest Patents
Gursel Aktan holds 1 patent for his invention titled "Combination of a PD-1 antagonist and eribulin for treating cancer." This patent describes combination therapies that include an antagonist of the Programmed Death 1 receptor (PD-1) and eribulin or a pharmaceutically acceptable salt thereof. The disclosure emphasizes the potential of these combination therapies for the treatment of cancer.
Career Highlights
Throughout his career, Gursel Aktan has worked with prominent companies in the pharmaceutical industry. He has been associated with Eisai R&D Management Co., Ltd. and Merck Sharp & Dohme Corp. His experience in these organizations has contributed to his expertise in developing innovative cancer therapies.
Collaborations
Gursel Aktan has collaborated with esteemed colleagues in his field, including Junji Matsui and Vassiliki Karantza. These collaborations have further enriched his research and development endeavors.
Conclusion
Gursel Aktan's contributions to cancer treatment through his innovative patent and collaborations with leading professionals highlight his commitment to advancing medical science. His work continues to inspire future innovations in the field of oncology.